UroGen Pharma Ltd. (NASDAQ:URGN) Receives $43.70 Average Price Target from Analysts

UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) has been given a consensus rating of "Buy" by the six brokerages that are currently covering the company, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $43.70.

A number of research analysts have recently commented on URGN shares. Oppenheimer restated an "outperform" rating and set a $40.00 price target on shares of UroGen Pharma in a research report on Wednesday, October 16th. HC Wainwright reiterated a "buy" rating and set a $60.00 price objective on shares of UroGen Pharma in a research note on Tuesday, October 15th. EF Hutton Acquisition Co. I raised UroGen Pharma to a "strong-buy" rating in a research note on Monday, October 14th. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a research report on Thursday.

Institutional Trading of UroGen Pharma

Hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC raised its position in shares of UroGen Pharma by 44.1% during the fourth quarter. SG Americas Securities LLC now owns 20,269 shares of the company's stock valued at $216,000 after buying an additional 6,207 shares during the last quarter. JPMorgan Chase & Co. raised its stake in UroGen Pharma by 263.1% during the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company's stock valued at $864,000 after purchasing an additional 49,318 shares in the last quarter. Tidal Investments LLC lifted its position in UroGen Pharma by 19.1% during the third quarter. Tidal Investments LLC now owns 37,595 shares of the company's stock valued at $477,000 after purchasing an additional 6,030 shares during the last quarter. Barclays PLC lifted its position in UroGen Pharma by 409.3% during the third quarter. Barclays PLC now owns 59,778 shares of the company's stock valued at $759,000 after purchasing an additional 48,040 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of UroGen Pharma by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 455,637 shares of the company's stock worth $5,787,000 after buying an additional 34,248 shares in the last quarter. Institutional investors own 91.29% of the company's stock.

UroGen Pharma Trading Up 0.9 %

UroGen Pharma stock traded up $0.09 during trading hours on Friday, reaching $10.24. The company had a trading volume of 143,649 shares, compared to its average volume of 384,610. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. UroGen Pharma has a 12-month low of $9.78 and a 12-month high of $20.70. The company has a 50-day moving average price of $11.20 and a 200 day moving average price of $12.95. The firm has a market cap of $240.17 million, a price-to-earnings ratio of -3.25 and a beta of 1.09.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, topping analysts' consensus estimates of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to the consensus estimate of $24.22 million. During the same quarter in the prior year, the business posted ($0.68) earnings per share. Equities analysts forecast that UroGen Pharma will post -3.1 earnings per share for the current year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.